troxacitabine has been researched along with Benign Neoplasms in 10 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (90.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW | 1 |
Beeram, M; Lin, CC; Ng, CM; Patnaik, A; Takimoto, CH | 1 |
Ecker, G | 1 |
Gourdeau, H; Jolivet, J | 1 |
Boudreau, C; Custeau, D; Dong, K; Gilbert, MJ; Gourdeau, H; Hamelin, B; Jolivet, J; Leblond, L; Ouellet, F; Richard, A | 1 |
Baker, SD; Capparelli, E; Giles, F; Hidalgo, M; Jolivet, J; Lee, CK; Li, J; Moore, MJ; Rowinsky, EK | 1 |
Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Lee, CK; Ma, WW; Messersmith, WA | 1 |
Baker, SD; de Bono, JS; Goetz, A; Hammond, LA; Hidalgo, M; Jolivet, J; Patnaik, A; Rowinsky, EK; Simmons, C; Siu, L; Stephenson, J; Weiss, G | 1 |
Baker, SD; Bélanger, K; Dionne, J; Jolivet, J; Maclean, M; Moore, M; Seymour, L; Siu, L; Soulières, D; Wainman, N | 1 |
1 review(s) available for troxacitabine and Benign Neoplasms
Article | Year |
---|---|
[Troxacitabine].
Topics: Acute Disease; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytosine; Dioxolanes; Drug Screening Assays, Antitumor; Humans; Leukemia; Neoplasms | 2004 |
5 trial(s) available for troxacitabine and Benign Neoplasms
Article | Year |
---|---|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Tissue Distribution; Treatment Outcome; Young Adult | 2009 |
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Topics: Antineoplastic Agents; Body Fluid Compartments; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Humans; Infusions, Intravenous; Kidney Function Tests; Male; Middle Aged; Models, Biological; Molecular Structure; Neoplasms; Predictive Value of Tests; Structure-Activity Relationship | 2006 |
Phase I study of troxacitabine administered by continuous infusion in subjects with advanced solid malignancies.
Topics: Adult; Aged; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Predictive Value of Tests; Probability; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Eruptions; Female; Half-Life; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Regression Analysis; Salvage Therapy; Statistics, Nonparametric; Stereoisomerism; Structure-Activity Relationship | 2002 |
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxolanes; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Thrombocytopenia; Tissue Distribution | 2002 |
4 other study(ies) available for troxacitabine and Benign Neoplasms
Article | Year |
---|---|
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Female; Humans; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neoplasms; Neutropenia; Young Adult | 2011 |
Troxacitabine (Shire Pharmaceuticals).
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Humans; Neoplasms; Structure-Activity Relationship | 2002 |
Troxacitabine: BCH 4556, SPD 758, Troxatyl.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytosine; Dioxolanes; Drug Industry; Humans; Infusions, Intravenous; Neoplasms; Treatment Outcome | 2003 |
Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Male; Mice; Neoplasm Transplantation; Neoplasms; Species Specificity; Time Factors | 2004 |